DMEMEDS shared post via Reuters: Glaxo, Genmab say disappointed with study of lymphoma treatment

(Reuters) - GlaxoSmithKline and Danish biotech company Genmab said disappointing results from a study on treating relapsed lymphoma with their ofatumumab drug meant it was unlikely they would seek its regulatory approval. [Category: healthNews] http://feeds.reuters.com/~r/reuters/healthNews/~3/-TWscCf2JTM/story01.htm

Read More